Treatment of melanoma-associated retinopathy

Steven F. Powell, Arkadiusz Z Dudek

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Opinion statement: Melanoma-associated retinopathy is a rare paraneoplastic disorder that is challenging to diagnose and even more difficult to treat. Because of the rarity of the disease, therapy is based on analysis of case series and case reports. Based on evidence from these reports, first-line therapy is cytoreduction of metastatic disease through metastasectomy, chemotherapy, and radiation. This can be combined with intravenous immunoglobulin. For refractory visual symptoms, additional therapies include systemic corticosteroids and plasmapheresis, but the success of these strategies has been limited. Because of the rarity of the disorder, new therapies should be evaluated and reported in the literature to expand our clinical understanding of this autoimmune disease.

Original languageEnglish (US)
Pages (from-to)54-63
Number of pages10
JournalCurrent Treatment Options in Neurology
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint Dive into the research topics of 'Treatment of melanoma-associated retinopathy'. Together they form a unique fingerprint.

Cite this